scholarly journals Certain properties of .ALPHA.-glucosidase from Mucor racemosus.

1977 ◽  
Vol 41 (9) ◽  
pp. 1559-1565 ◽  
Author(s):  
Yoshiki YAMASAKI ◽  
Yukio SUZUKI ◽  
Junjiro OZAWA
Keyword(s):  
Mucor Racemosus ◽  
Alpha Glucosidase

scholarly journals Purification and properties of .ALPHA.-glucosidase from Mucor racemosus.

1977 ◽  
Vol 41 (9) ◽  
pp. 1553-1558 ◽  
Author(s):  
Yoshiki YAMASAKI ◽  
Yukio SUZUKI ◽  
Junjiro OZAWA
Keyword(s):  
Mucor Racemosus ◽  
Purification And Properties ◽  
Alpha Glucosidase

TOTAL POLYPHENOL CONTENT, FREE RADICAL SCAVENGING, ALPHA-GLUCOSIDASE INHIBITION CAPACITY, THE EFFICACY IN CONTROLLING BLOOD GLUCOSE OF DIABETIC RATS OF THE MIXTURE VOS EXTRACTED FROM THE LEAVES OF CLEISTOCALYX OPERCULATUS, PSIDIUM GUAJAVA AND NELUMBO NUCIFERA

2013 ◽  
pp. 50-55
Author(s):  
Tuyet Mai Truong ◽  
Thi Lam Nguyen ◽  
Lan Anh Pham ◽  
Hoang Kien Truong
Keyword(s):  
Body Weight ◽  
Blood Glucose ◽  
Radical Scavenging ◽  
Psidium Guajava ◽  
Free Radical Scavenging ◽  
Diabetic Mice ◽  
Cleistocalyx Operculatus ◽  
Prevention And Treatment ◽  
Treatment Of Diabetes ◽  
Alpha Glucosidase

Objective: Plant polyphenols have antioxidant capacity and alpha-glucosidase inhibition to supporting for prevention and treatment of diabetes. Materials and Method: Present study was conducted to determine the content of total polyphenols, free radical scavenging and alpha-glucosidase inhibition of the VOS mixture that extracted from leaves (Voi leaves - Cleistocalyx operculatus (V), Oi leaves - Psidium guajava (O), Sen leaves - Nelumbo nucifera (S)). Results: The efficacy of blood glucose controlling in diabetic mice was investigated. After 8 weeks of administration with 200 mg VOS/kg body weight and 400 mg VOS/kg body weight, VOS diabetic mice had significantly reduced blood glucose level as compared to control diabetic mice. VOS diabetic mice with 400 mg dosage are lower in blood glucose levels than that of the diabetic mice with 200 mg. Also, the significant reducing in HbA1c was observed in VOS diabetic mice as compared with control diabetic mice. Conclusion: VOS-product extracted from Cleistocalyx operculatus leaves, guava leaves, lotus leaves might be considered as a safe product and to be a potential product in the supporting of prevention and treatment of diabetes.

Recent Developments in Alpha-Glucosidase Inhibitors for Management of Type-2 Diabetes: An Update

2019 ◽  
Vol 25 (23) ◽  
pp. 2510-2525 ◽  
Author(s):  
Bashir Usman ◽  
Neha Sharma ◽  
Saurabh Satija ◽  
Meenu Mehta ◽  
Manish Vyas ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Patient Compliance ◽  
Postprandial Hyperglycemia ◽  
Diabetic Patients ◽  
Poor Patient ◽  
Glucosidase Inhibitors ◽  
Poor Patient Compliance ◽  
Recent Developments ◽  
Alpha Glucosidase

The incidence of diabetes has increased globally in recent years and figures of diabetic patients were estimated to rise up to 642 million by 2040. The disorder is accompanied with various complications if not managed at the early stages, and interlinked high mortality rate and morbidity with time. Different classes of drugs are available for the management of type 2 diabetes but were having certain limitations of their safety. Alphaglucosidase is a family of enzyme originated from the pancreas which plays a role in the anabolism of 80-90% of carbohydrate consumed into glucose. This glucose is absorbed into the blood and results in frank postprandial hyperglycemia and worsens the conditions of diabetic patients which precipitate complications. Inhibition of these enzymes helps to prevent postprandial hyperglycemia and the formation of glycated end products. Alphaglucosidase inhibitors are reported to be more important in adequate control of type 2, but marketed drugs have various side effects, such as poor patient compliance and also expensive. This proves the needs for other class of drugs with better efficacy, safety, patient compliance and economic. In this review, we have emphasized the recent advances in the field of new alpha-glucosidase inhibitors with improved safety and pharmacological profile.

scholarly journals Modeling CNS Involvement in Pompe Disease Using Neural Stem Cells Generated from Patient-Derived Induced Pluripotent Stem Cells

Cells ◽  
2020 ◽  
Vol 10 (1) ◽  
pp. 8
Author(s):  
Yu-Shan Cheng ◽  
Shu Yang ◽  
Junjie Hong ◽  
Rong Li ◽  
Jeanette Beers ◽  
...  
Keyword(s):  
Stem Cells ◽  
Neural Stem Cells ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Pompe Disease ◽  
Drug Efficacy ◽  
Cns Involvement ◽  
Glycogen Accumulation ◽  
Induced Pluripotent ◽  
Alpha Glucosidase

Pompe disease is a lysosomal storage disorder caused by autosomal recessive mutations in the acid alpha-glucosidase (GAA) gene. Acid alpha-glucosidase deficiency leads to abnormal glycogen accumulation in patient cells. Given the increasing evidence of central nervous system (CNS) involvement in classic infantile Pompe disease, we used neural stem cells, differentiated from patient induced pluripotent stem cells, to model the neuronal phenotype of Pompe disease. These Pompe neural stem cells exhibited disease-related phenotypes including glycogen accumulation, increased lysosomal staining, and secondary lipid buildup. These morphological phenotypes in patient neural stem cells provided a tool for drug efficacy evaluation. Two potential therapeutic agents, hydroxypropyl-β-cyclodextrin and δ-tocopherol, were tested along with recombinant human acid alpha-glucosidase (rhGAA) in this cell-based Pompe model. Treatment with rhGAA reduced LysoTracker staining in Pompe neural stem cells, indicating reduced lysosome size. Additionally, treatment of diseased neural stem cells with the combination of hydroxypropyl-β-cyclodextrin and δ-tocopherol significantly reduced the disease phenotypes. These results demonstrated patient-derived Pompe neural stem cells could be used as a model to study disease pathogenesis, to evaluate drug efficacy, and to screen compounds for drug discovery in the context of correcting CNS defects.

Sign in / Sign up

Export Citation Format

Share Document